logo

For the Inventor, By the Inventor

Nanjing, China

Impact Therapeutics, Inc.

Calculating rank
USPTO Granted Patents = 11


Forward Citations = 25

Loading Chart...
Loading Chart...

27 inventors (with patents filed for the assignee):

goldMedal Ye Edward Tian (8 out of 16 patents)

silverMedal Sui Xiong Cai (5 out of 11 patents)

bronzeMedal Suixiong Cai (5 out of 9 patents)

4.  Qingbing Xu (4 out of 4 patents)

5.  Lizhen Wu (4 out of 5 patents)

6.  Lijun Liu (4 out of 5 patents)

7.  Yangzhen Jiang (4 out of 4 patents)

8.  Guoxiang Wang (4 out of 4 patents)

9.  Feng Yin (4 out of 5 patents)

10.  Chengyun Gu (4 out of 4 patents)

11.  Xiuhua Hu (4 out of 4 patents)

12.  Xiaozhu Wang (4 out of 10 patents)

13.  Sishun Kang (4 out of 4 patents)

14.  Shengzhi Chen (4 out of 4 patents)

15.  Haijun Dong (3 out of 5 patents)


11 patents:

1. 11358955 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2022-06-14),
2. 11179392 - Solid pharmaceutical formulation of PARP inhibitors and use thereof (2021-11-23),
3. 10874670 - Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof (2020-12-29),
4. 10703759 - 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones (2020-07-07),
5. 10676468 - N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof (2020-06-09),
6. 10562889 - Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones (2020-02-18),
7. 10316027 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2019-06-11),
8. 9926304 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2018-03-27),
9. 9290460 - [object Object] (2016-03-22),
10. 9102631 - 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof (2015-08-11),
11. 9090568 - Quinazolinediones and their use (2015-07-28),
Company Overview
Impact Therapeutics, Inc. is a biopharmaceutical company based in Nanjing, China, focused on the development of innovative cancer therapies. The organization specializes in precision medicine, leveraging advanced research to create targeted treatments that address specific genetic profiles of tumors. With a commitment to improving patient outcomes, Impact Therapeutics is engaged in various stages of drug development, including preclinical and clinical trials, aiming to bring novel therapies to market that can significantly enhance cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

11 Patents

#42 in Nanjing

#2,575 in China

#51,873 in the World

Nanjing, CN
Nanjing, China

Impact Therapeutics, Inc.

Forward Citations = 25

27 inventors:

goldMedal Ye Edward Tian (8 out of 16 patents)

silverMedal Sui Xiong Cai (5 out of 11 patents)

bronzeMedal Suixiong Cai (5 out of 9 patents)

4.  Qingbing Xu (4 out of 4 patents)

5.  Lizhen Wu (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Impact Therapeutics, Inc.. Retrieved from https://idiyas.com/company/impact-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…